Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopy Clear all
Completed Phase 2 Interventional Results available

A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis

NCT03706040
View directory record Official record
Conditions
Dermatitis
Interventions
Placebo, Risankizumab
Biological
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
39
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Not applicable Interventional

Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis

NCT07746427
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Digital App Mindfulness Meditation, Mindfulness Meditation Sheet
Behavioral
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
13 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06130566
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
42
States / cities
Scottsdale, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

NCT01782703
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
0 Months to 17 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Northbrook, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 4 Interventional Results available

Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial

NCT05590585
View directory record Official record
Conditions
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Interventions
dupilumab, Topical emollient (moisturizer)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
30
States / cities
Birmingham, Alabama • Montgomery, Alabama • Fremont, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Study to Examine the Benefits of Fabric Made With Lyocell/Chitosan/Ceramide in the Treatment of Children With Mild to Moderate Eczema

NCT02224950
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Non-medicated Emollient plus Lyocell/Chitosan Sleeve, Non-medicated Emollient plus Cotton Sleeve, Placebo Sleeve
Device · Other
Lead sponsor
University of Minnesota
Other
Eligibility
3 Months to 5 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2017 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT04990440
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Bermekimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
6
States / cities
Indianapolis, Indiana • Chesterfield, Michigan • Tulsa, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 23, 2026, 7:26 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

FIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients

NCT06564389
View directory record Official record
Conditions
Healthy Participants, Atopic Dermatitis
Interventions
PF-07832837, Placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Anaheim, California • San Diego, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

ASPIRE: PROs & Caregiver Burden in Children With Atopic Dermatitis

NCT03645057
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Tacrolimus 0.03% Ointment
Drug
Lead sponsor
University of Rochester
Other
Eligibility
2 Years to 15 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

NCT04664153
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment, Vehicle ointment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2022 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Screening for Filaggrin Mutation in Atopic Dermatitis and Ichthyosis Vulgaris in the African American Population

NCT01016106
View directory record Official record
Conditions
Atopic Dermatitis, Ichthyosis Vulgaris
Interventions
Buccal Swab
Genetic
Lead sponsor
Northwestern University
Other
Eligibility
6 Months and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis

NCT04040192
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months and older
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Fountain Valley, California • Fremont, California • Colorado Springs, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2023 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

An Evaluation of LEO 138559 in Adults With Moderate to Severe Atopic Dermatitis.

NCT04922021
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
LEO 138559, LEO 138559 placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 64 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Birmingham, Alabama • Fountain Valley, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

NCT06998056
View directory record Official record
Conditions
Atopic Dermatitis (Eczema)
Interventions
ARQ-151 cream 0.05%
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
3 Months to 2 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
17
States / cities
Birmingham, Alabama • Bryant, Arkansas • Fountain Valley, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Not listed No phase listed Observational

Systemic Therapies for Pediatric Atopic Dermatitis

NCT01447381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Not listed
Lead sponsor
Rady Children's Hospital, San Diego
Other
Eligibility
2 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
3
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

NCT03002571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IDP-124 Lotion, IDP-124 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years and older
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT04345367
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib 200 mg, Dupilumab 300 mg
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Subcutaneous Lirentelimab (AK002) in Atopic Dermatitis

NCT05155085
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
AK002, Placebo
Drug · Other
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Cullman, Alabama • Gilbert, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 2 Interventional

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

NCT05935085
View directory record Official record
Conditions
Atopic Dermatitis Eczema
Interventions
ANB032, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
41
States / cities
Anaheim, California • Cerritos, California • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 4 Interventional Results available

The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.

NCT05696392
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ruxolitinib cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
30
States / cities
Fountain Valley, California • Long Beach, California • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Topical NanoDox® for Atopic Dermatitis

NCT02910011
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Nanodox 1% (doxycycline monohydrate hydrogel)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 2 Interventional Results available

Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis

NCT01941537
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ILV-094, Placebo Comparator
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Oct 23, 2026, 7:26 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection

NCT05732454
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis, Unspecified, Eczema, Eczema, Atopic
Interventions
etrasimod, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
44
States / cities
Fountain Valley, California • Laguna Hills, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 23, 2026, 7:26 PM EDT
Completed Phase 3 Interventional Results available

Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3

NCT03363854
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
21
States / cities
Birmingham, Alabama • Encinitas, California • Fountain Valley, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 23, 2026, 7:26 PM EDT